# KalVista Pharmaceuticals, Inc. (KALV) — merger [completed]
Source: SEC API (secapi.ai) · situation sit_2f03eced1b532ce8113f · retrieved 2026-08-11T16:02:32.717Z

## Overview
KalVista Pharmaceuticals, Inc. is a commercial-stage pharmaceutical company developing treatments for hereditary angioedema (HAE) and other rare diseases.

Chiesi Farmaceutici S.p.A. (Parent) and its wholly owned subsidiary Skyline Merger Sub, Inc. (Purchaser) launched a tender offer to acquire all outstanding shares of KalVista Pharmaceuticals, Inc. for $27.00 per share in cash, representing an implied total equity valuation of approximately $1.9 billion. The offer was announced on April 29, 2026, following a series of proposals from Parent beginning in February 2026 at $24.00 per share, revised to $26.50 per share in March 2026, and further revised to $26.50 per share plus a contingent value right (CVR) of $1.00 per share on April 28, 2026, before Parent submitted its final proposal of $27.00 per share in cash on April 28, 2026. The Offer Price of $27.00 per share represented a 41% premium to the Company's closing trading price on April 27, 2026.

## Terms
- Counterparty: Chiesi Farmaceutici S.p.A. · Deal value: $1.90B · Consideration: cash · Premium: 41.0% · Stake: 100% · Price/share: $27

## Key dates
- Announced 2026-06-01 · Completed 2026-06-11

## Timeline
- 2026-06-01 · SC 14D9/A (0001140361-26-023453): SC 14D9/A - KalVista Pharmaceuticals, Inc. — *KalVista Pharmaceuticals, Inc. is a commercial-stage pharmaceutical company developing treatments for hereditary angioedema (HAE) and other rare diseases.* Chiesi Farmaceutici S.p.A. (Parent) and its wholly owned subsidiary Skyline Merger Sub, Inc. (Purchaser) launched a tender offer to acquire all outstanding shares of KalVista Pharmaceuticals, Inc. for $27.00 per share in cash, representing an implied total equity valuation of approximately $1.9 billion. The offer was announced on April 29, 2026, following a series of proposals from Parent beginning in February 2026 at $24.00 per share, revised to $26.50 per share in March 2026, and further revised to $26.50 per share plus a contingent value right (CVR) of $1.00 per share on April 28, 2026, before Parent submitted its final proposal of $27.00 per share in cash on April 28, 2026. The Offer Price of $27.00 per share represented a 41% premium to the Company's closing trading price on April 27, 2026.
  https://www.sec.gov/Archives/edgar/data/1348911/0001140361-26-023453.txt
- 2026-06-11 · SC 14D9/A (0001140361-26-024885): SC 14D9/A SC 14D9/A
  https://www.sec.gov/Archives/edgar/data/1348911/000114036126024885/ny20075902x1_sc14d9a.htm
- 2026-06-11 · 8-K (0001140361-26-024949): 8-K FORM 8-K
  https://www.sec.gov/Archives/edgar/data/1348911/000114036126024949/ny20075902x2_8k.htm

## Citations
- 0001140361-26-023453 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000114036126023453
- 0001140361-26-024885 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000114036126024885
- 0001140361-26-024949 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000114036126024949